Obermatt

Recordati

MIL:REC · IT0003828271
PharmaceuticalsLarge

360

54
EV / EBIT48
Price / Owner Earnings69
Owner Earnings Yield64
Dividend Yield81
Price/Sales56
EV / Gross Profit38
Price/Book40
Return on Capital73
Cash Return on Capital68
Return on Equity83
EBIT Margin84
Gross Profitability40
Cash Conversion46
Accruals63
Owner Earnings Margin81
Sales growth57
Profit Growth67
Long-Term EPS Growth54
Owner Earnings Growth56
Reinvestment76
Price momentum36
Debt load19
Refinancing68
Debt Payback21
Liquidity57
Analyst ratings33
Opinion Changes6
Price Target Upside60
Market mood41
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Recordati generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryItaly
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeBIT
Employees1,693
ISINIT0003828271
Last UpdateApr 2, 2026
Themes
OphthalmologyCardiovascularHematologyNeurologyCentral Nervous SystemGastroenterologyE-CommerceInternet

Description

Analysis

Quality compounder

Recordati Industria Chimica e Farmaceutica S.p.A. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is fair. The owner-earnings multiple stands at 16.6×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 4% a year, against analyst forecasts of 12%. The price, in other words, assumes less than the experts do.

Growth is moderate; the safety picture is stretched. The company scores 20/20 on our value-creation score: strong value creator.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
62
2023202420252026

All-time high

78

Mar 2026

All-time low

8

Jan 2025

Average rank

51

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
56
17
31
27
Price/Earnings
51
34
46
44
Price/Book
40
10
17
24
Dividend Yield
81
62
61
82
Value (overall)
67
27
28
47

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Recordati with its peers
UCB
BRU:UCB
69
CountryBelgium
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Virbac
PAR:VIRP
58
CountryFrance
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Perrigo
NYQ:PRGO
8
CountryIreland
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
GSK
LSE:GSK
72
CountryUK
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Euroapi
PAR:EAPI
37
CountryFrance
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Laboratorios Farmaceuticos Rovi
MCE:ROVI
46
CountrySpain
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →